secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062027
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q3 2023: cash $141.4M, BDC-1001 29% ORR, BDC-3042 dosed
----------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $141.4M as of Sept 30, 2023; expected to fund operations through 2025.
- Collaboration revenue $2.5M (vs $2.1M Q3 2022); R&D expenses $15.0M (down from $19.0M).
- Loss from operations of $18.2M vs $22.3M in prior year quarter.
- BDC-1001 Phase 1 updated data: 29% ORR monotherapy; first complete response; well tolerated; Orphan Drug Designation for gastric cancers.
- First patient dosed with BDC-3042 in Phase 1/2 for advanced solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017023062027/0000950170-23-062027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017023062027/bolt-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer